Medicine:Neuromyelitis optica spectrum disorder

From HandWiki
Revision as of 02:47, 5 February 2024 by John Stpola (talk | contribs) (fix)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Neuromyelitis optica spectrum disorders
Other namesNeuromyelitis optica (NMO), Devic's disease, Devic's syndrome
SpecialtyNeurology, ophthalmology
SymptomsVision loss, sensory loss, weakness, bladder dysfunction
Usual onsetMedian: age 40 for AQP4-IgG, age 31 for MOG-IgG[1]
TypesAQP4-IgG-positive, MOG-IgG-positive (recurrent, monophasic)[1]
Risk factorsFemale sex, genetic factors[1]
Diagnostic methodSymptoms, blood antibody titers, MRI
Differential diagnosisMultiple sclerosis, various autoimmune disorders
MedicationEculizumab, inebilizumab, satralizumab, rituximab, methylprednisolone, azathioprine, cellCept, mitoxantrone, methotrexate, intravenous immunoglobulin, cyclophosphamide
FrequencyUp to 1 in 10,000[1]

Neuromyelitis optica spectrum disorders (NMOSD) are a spectrum of autoimmune diseases characterized by acute inflammation of the optic nerve (optic neuritis, ON) and the spinal cord (myelitis).[1][2][3] Episodes of ON and myelitis can be simultaneous or successive. A relapsing disease course is common, especially in untreated patients.[1][4]

  • Neuromyelitis optica (NMO) is a particular disease within the NMOSD spectrum. It is characterised by optic neuritis and longitudinally extensive myelitis. In more than 80% of NMO cases, the cause is immunoglobulin G autoantibodies to aquaporin 4 (anti-AQP4), the most abundant water channel protein in the central nervous system.[5][1][4]
  • Less common diseases with other manifestations are also part of the NMOSD spectrum.[6][4]

Signs and symptoms

The signs and symptoms of NMOSD depend on the neurologic structures the disease affects, and, to some extent, the antibodies involved.

Spinal cord effects

The most common initial manifestation of the disease is inflammation of the spinal cord (myelitis).[4] Myelitis causes spinal cord dysfunction, which can result in muscle weakness, paralysis in the limbs, lost or reduced sensation, spasms, loss of bladder and bowel control, or erectile dysfunction.[1][4][2][7][8][9] The myelitis can be transverse, affecting an entire cross-section of the spinal cord, and showing bilateral symptoms.

Optic effects

The second most common initial manifestation of the disease is inflammation of the optic nerve and/or optic chiasm (optic neuritis, ON).[4] ON may lead to varying degrees of visual impairment with decreased visual acuity, although visual field defects, or loss of color vision, may occur in isolation or prior to formal loss of visual acuity. Compared to idiopathic ON and ON due to multiple sclerosis (MS), ON due to NMOSD more often results in severe visual loss at onset, with bilateral involvement, and permanent visual deficits.[4]

Brain effects

Less commonly than the spinal cord and optic nerve, NMOSD can affect the brain stem.[4] Lesions in the brain stem or upper cervical spinal cord can cause respiratory insufficiency. Lesions in the area postrema of the medulla oblongata can cause vomiting or hiccups, as well as pain and tonic spasms.[1][4] Additional brain lesions are common but often asymptomatic (though cognitive deficits, as well as depression, may be underdiagnosed sequalae). Lesions may also affect the diencephalon, mostly in Aquaporin-4–Immunoglobulin-G (AQP4-IgG) NMOSD.[1][4]

Disease course

Signs and symptoms usually follow a relapsing and remitting course, but occasionally can be progressive (monophasic). Deficits can be temporary or permanent, the latter especially in the absence of treatment.[citation needed]

Fatigue

Fatigue is a common symptom, with studies showing that as many as 77% of people with NMOSD have fatigue.[10][11] Fatigue has been found to correlate with quality of life in people with NMOSD.[12][13]

Comparison with MS

NMO and multiple sclerosis (MS) can be similar in clinical and radiological presentation, and MS may very rarely present with an NMO-like phenotype (e.g. in patients with long-standing MS resulting in confluent spinal cord lesions mimicking the longitudinally extensive spinal cord lesions typically seen in NMO). In consequence, NMO was in the past wrongly considered a clinical variant of MS. However, NMO is not related to MS in the vast majority of cases and differs from MS substantially in terms of pathogenesis, clinical presentation, magnetic resonance imaging, cerebrospinal fluid findings, disease course, and prognosis.[1]

Causes

NMOSD is caused by an autoimmune attack on the nervous system. In more than 80% of cases, IgG autoantibodies against aquaporin-4 (anti-AQP4+) are the cause, and in 10–40% of the remaining cases, IgG antibodies against MOG are the cause.[1] The cause of the remaining cases is still unknown, and it is likely heterogeneous.[14][15]

Why autoimmunity develops is largely unknown. Multiple genetic and environmental factors are known to increase the risk of developing NMOSD. The strongest risk factor is being female, especially in AQP4-IgG-positive NMOSD.[1] Multiple human leukocyte antigen (HLA) alleles are associated with NMOSD.[1]

NMO was associated in the past with many systemic diseases. Some researchers have pointed out that some other cases could be paraneoplastic.[16] It appears that lupus can produce NMO-IgG autoantibodies, leading to cases of lupus-derived NMO.[17]

The discovery of NMO-IgG (anti-AQP4) has opened a new avenue of research into the causes.[citation needed]

Pathophysiology

Illustration of the four different types of glial cells found in the central nervous system: ependymal cells, astrocytes, microglial cells, and oligodendrocytes

Anti-AQP4+ variants

Main page: Medicine:Anti-AQP4 disease

NMOSD is usually caused by autoantibodies targeting aquaporin 4 (AQP4), a channel protein in the cell membrane that allows water to pass through the membrane.[18] AQP4 monomers form tetramers, and the tetramers aggregate.[4] AQP4 is found in astrocytes, which are the basis for the glymphatic system.[19] Thus, NMOSD involving AQP4-IgG can be considered an astrocytopathy[20] or autoimmune astrocytic channelopathy, since the astrocytes are semi-selectively destroyed.[21]

The astrocytes surround the blood–brain barrier (BBB), a system responsible for preventing substances in the blood from entering the brain. For antibodies from the blood to reach astrocytes in the central nervous system (CNS), they must cross the BBB, the mechanism of which is not completely known. Some reports point to the metalloproteinase-2 and interleukin-6 as culprits responsible for the BBB failure.[22] There is broad consensus that AQP4/NMO-IgG initially enters the brain via BBB-deficient sites such as the area postrema, where there is access to cerebrospinal fluid (CSF).[23] In any case, anti-AQP4 is produced mainly intrathecally.[24]

Within astrocytes, AQP4 is primarily found in astrocytic foot processes that abut blood vessels and the linings of the brain (meninges).[1] NMOSD brain lesions, as seen under a microscope, show IgG, Immunoglobulin M (IgM), inflammatory cells, and complement deposits around blood vessels.[1] AQP4-IgG is a member of the IgG1 immunoglobulin family, which is an activator of the complement system, which seems to play an integral part in the autoimmune response.[1] There is a loss of astrocytes, and sometimes also a loss of neurons and oligodendrocytes. Loss of cells other than astrocytes is a consequence of collateral inflammatory damage or astrocyte dysfunction.[1]

NMOSD selectively affects the optic nerve, spinal cord, and brain stem. This selectivity can be explained by the increased amount of AQP4 in these structures, and, furthermore, by the increased amount of AQP4 aggregates in the optic nerve and spinal cord.[1] The increased BBB permeability at the area postrema helps explain involvement there.[1] AQP4 is present in tissues outside the central nervous system (e.g. the kidneys), but these tissues aren't affected in NMOSD, at least in part because of the presence of autoimmune downregulators outside of the central nervous system.[1]

In NMOSD, areas of brain tissue that appear normal in conventional magnetic resonance imaging (MRI) can show damage in diffusion tensor imaging (DTI), although less so compared to multiple sclerosis (MS).[25]

Most research into the pathology of NMO has focused on the spinal cord. The damage can range from inflammatory demyelination to necrotic damage of the white and grey matters. The inflammatory lesions in NMO have been classified as type II lesions (complement-mediated demyelination), but they differ from MS pattern II lesions in their prominent perivascular distribution. Therefore, the pattern of inflammation is often quite distinct from that seen in MS.[18][26]

AQP4-IgG levels are coarsely correlated with NMOSD disease activity, those levels generally increasing before relapse and declining during remission, with higher levels being correlated to more severe disease manifestation.[1]

NMO-IgG-negative cases are less understood. It seems that astrocytes are spared in these cases.[27]

Anti-MOG+ variants

The second most frequent autoantibody in NMO is MOG-IgG, which targets myelin oligodendrocyte glycoprotein (MOG). MOG is an integral membrane glycoprotein found on the surface of oligodendrocytes and the outermost surface of myelin sheaths.[1] Its function is not entirely known.[1] MOG-IgG is produced outside the central nervous system (CNS) despite MOG existing only in the CNS (with the BBB separating the two), leading to the hypothesis that MOG drained via cerebral spinal fluid into lymph nodes causes autoimmune reaction formation.[1]

MOG-IgG-positive NMOSD brain lesions, as seen under a microscopic, show demyelination with preservation of oligodendrocytes and axons, presence of inflammatory cells, and IgG and complement deposits.[1] MOG-IgG levels coarsely correlate with disease severity, with levels being higher during active disease, and higher levels being associated with more severe disease manifestation.[1]

Antibodies against MOG are considered mostly absent in similar diseases, such as MS.[28] Therefore, it can be said that anti-MOG diseases are grouped within AQP4-IgG-negative NMOSD.[29]

Together with anti-AQP4 disease, anti-MOG diseases form the wider part of the NMO spectrum. The NMO cases are classified in four classes, according to the presence or absence of any of these two main auto-antibodies.[30]

The clinical course and the response to therapy is different for various diseases classed within these groups, showing a better prognosis for those in the NMO-Ab(−)/MOG-Ab(−) group, and a worse prognosis for those in the NMO-Ab(+)/MOG-Ab(+) group.[30] The MOG-related NMO can be radiologically identified by the conus involvement. Myelin-oligodendrocyte glycoprotein antibody–positive patients were more likely to have conus involvement on spinal magnetic resonance imaging.[31]

Diagnosis

MRI image of a patient with transverse myelitis, one of the diagnostic criteria for NMOSD

NMOSD is diagnosed using consensus clinical criteria, which have undergone multiple revisions, most recently in 2015.[32][33]

Diagnostic criteria are more relaxed for seropositive AQP4–IgG cases than they are for seronegative AQP4-IgG ones. If AQP4-IgG is detected, then one core clinical criterion, along with the ruling out of alternative diagnoses, is sufficient for NMOSD diagnosis.[34]

If AQP4-IgG is undetected, or its status is unknown, two core clinical criteria, each with supportive MRI findings, along with the ruling out of alternative diagnoses, are needed for an NMOSD diagnosis.[35]

NMOSD diagnostic criteria[34]
Core criteria Additional MRI findings for absent/unknown AQP4-IgG
Optic neuritis Either 1) brain MRI showing normal findings or only nonspecific white matter lesions, or 2) optic nerve MRI showing T2-hyperintensity, or T1 enhancing lesion, greater than 1/2 optic nerve length or involving optic chiasm
Acute myelitis intramedullary lesion > 3 contiguous segments, or spinal atrophy ≥ 3 contiguous segments
Area Postrema Syndrome (prolonged episodes of hiccuping or vomiting/nausea) dorsal medulla/area postrema lesions
Acute brainstem syndrome periependymal brainstem lesions
Symptomatic narcolepsy/acute diencephalic clinical syndrome with an MRI showing diencephalon lesion(s) None additional
Symptomatic cerebral syndrome with NMOSD-typical brain lesion(s) None additional

Rarely, it has been reported that some courses of anti-NMDAR are consistent with NMO.[36] Preliminary reports suggest that other autoantibodies may play a role in rare cases of NMO.[37][38]

NMOSD with MOG-IgG is considered a manifestation of anti-MOG associated encephalomyelitis.[39]

Spectrum constituents

After the development of the NMO-IgG test, the spectrum of disorders comprising NMO was expanded. The spectrum is now believed to consist of:

Differential diagnosis

AQP4-Ab-negative NMO presents problems for differential diagnosis. The behavior of the oligoclonal bands can help to establish a more accurate diagnosis. Oligoclonal bands in NMO are rare and they tend to disappear after attacks, while in MS they are nearly always present and persistent.[44] It is important to notice for differential diagnosis that, though uncommon, it is possible to have longitudinal lesions in MS.[45]

Another problem for diagnosis is that AQP4-ab in MOG-ab levels can be too low to be detected. Some additional biomarkers have been proposed.[46][47]

NMO differs from MS in that it usually has more severe sequelae after an acute episode than standard MS, which infrequently presents as transverse myelitis. In addition oligoclonal bands in the CSF as well as white matter lesions on brain MRIs are uncommon in NMO, but occur in over 90% of MS patients.[48]

Recently, the presence of AQP4 has been found to distinguish standard MS from NMO; but as MS is a heterogeneous condition,[49] and some MS cases are reported to be Kir4.1 channelopathies[50] (autoimmunity against the potassium channels), it is still possible to consider NMO as part of the MS spectrum. Besides, some NMO-AQP4(−) variants are not astrocytopathic, but demyelinating.[51]

Tumefactive demyelinating lesions in NMO are not usual, but they have been reported to appear in several cases mistakenly treated with interferon beta.[52]

Also, an overlap with Sjögren syndrome has been reported.[53]

Evolution of diagnostic criteria

Since the discovery of the AQP4 autoantibody, it has been found that it appears also in patients with NMO-like symptoms that do not fulfill the clinical requirements to be diagnosed with NMO (recurrent and simultaneous optic nerve and spinal cord inflammation).[54]

The term neuromyelitis optica spectrum disorders (NMOSD) has been designed to allow incorporation of cases associated with non-AQP4 biomarkers.[33] Therefore, it includes all the clinical variants due to anti-AQP4, plus other non-related but clinically similar syndromes such as anti-MOG associated encephalomyelitis. Some cases with MOG+ and AQP4+ antibodies have been found.[33]

These variants are expected to respond to the same treatments as standard NMO.[55] Some authors propose to use the name "autoimmune aquaporin-4 channelopathy" for these diseases,[15] while others prefer a more generic term "AQP4-astrocytopathy", which also includes deficiencies of AQP4 with a non-autoimmune origin.[56]

Treatment

Chemical structure of methylprednisolone, which is used to treat attacks

There is no cure for NMO, but it is treatable. Some patients recover, but many are left with impairment of vision and limbs, which can be severe in some cases.[57]

Attacks

Long term neurologic deficits are the cumulative effects of acute attacks, emphasizing the importance of acute treatment.[1] Traditionally, attacks have been treated with short courses (3–5 days) of high dosage intravenous corticosteroids, such as methylprednisolone IV (Solu-Medrol).[58] Early initiation of treatment with steroids has been shown to improve vision-related outcomes after acute attacks.[1][59] However, there is no high-level evidence for steroids affecting long-term outcomes; this treatment strategy was borrowed from that for similar diseases (idiopathic optic neuritis and multiple sclerosis).[59][58]

Plasmapheresis can be an effective treatment when attacks progress after the administration of corticosteroids.[41] This treatment involves the patient's own blood being pumped out, blood cells being removed from the plasma and mixed with a solution, then the new blood mixture being pumped back in.[57]

Secondary prevention

Prophylactic treatment, to prevent relapses of NMO, is generally employed; but the exact duration of such treatment is debatable.[60]

FDA-approved pharmaceuticals

FDA-approved pharmaceuticals against AQP4-IgG-positive NMOSD, shown to be effective in phase III clinical trials, first became available in 2019.[1] As of 2020, they are among the most expensive drugs worldwide.[1] They are not available in pill form, which, along with their high price, limits their accessibility.[1] These new drugs' effectiveness against AQP4-IgG-negative NMOSD is unknown.[1]

Drug (brand) Brand Date of FDA approval Mechanism of action Note
Eculizumab Soliris 2019 Monoclonal antibody against complement protein C5 Approved for AQP4-IgG-positive NMOSD[61]
Inebilizumab Uplizna 2020 June Monoclonal antibody against CD19+ B cells [62]
Satralizumab Enspryng 2020 August Monoclonal antibody against IL-6 Approved forAQP4-IgG-positive NMOSD[63][64]

Off-label treatments

Many treatments are used despite the lack of phase III clinical trials testing their efficacy.[1] Neither inferiority nor superiority to the newer, FDA approved drugs has been clearly demonstrated; and, considering their being relatively inexpensive and being availability in pill format, these drugs are the current standard treatment.[1] Most of these medications affect the immune system in various ways.[58][41][65]

Drug (brand) Mechanism of action Note
azathioprine (Imuran, Azasan) Inhibits purine metabolism First reported effective in 1998 and was mainstay of treatment 10+ years thereafter. Sometimes combined with steroids due to months-long onset of action.[1]
mycophenolate mofetil (CellCept) Inhibits purine metabolism Has partially replaced azathioprine due to proposed better efficacy and tolerability. Sometimes combined with steroids due to months-long onset of action.[1]
corticosteroid [66]
mitoxantrone DNA synthesis/repair inhibitor
methotrexate Inhibits folate metabolism
cyclophosphamide DNA crosslinker
rituximab (Rituxan) antibody against CD20 – B cell depletion[67] The most commonly used treatment for NMOSD today.[68]
intravenous immunoglobulin (IVIG)
hematopoietic stem cell transplantation (HSCT) can be used in severe cases of NMO. Available data suggests that this procedure can reduce inflammatory activity in the short term, but a clear majority of the patients will relapse within 5 years.[69]

It is important to note that certain immunosuppressants used to treat MS—such as interferon-β, fingolimod, natalizumab, and alemtuzumab—worsen NMO disease progression and should not be used to treat NMO.[70]

Prognosis

Normally, some improvement appears in a few weeks, but severe residual symptoms and even disability may persist.[citation needed]

The disease can be monophasic, i.e. a single episode with permanent remission afterwards. However, at least 85% of patients have a relapsing form of the disease with repeated attacks of transverse myelitis and/or optic neuritis. In patients with the monophasic form, the transverse myelitis and optic neuritis occur simultaneously or within days of each other. On the other hand, patients with the relapsing form are more likely to have weeks or months between the initial attacks, and to have better motor recovery after the initial transverse myelitis event. Relapses usually occur early, with about 55% of patients having a relapse in the first year and 90% in the first five years.[18]

It is possible that the relapsing form is related to the anti-AQP4+ seropositive status and the monophasic form related to its absence.[71] Unlike MS, NMO rarely has a secondary progressive phase in which patients have increasing neurologic decline between attacks without remission. Instead, disabilities arise from the acute attacks.[18]

Approximately 20% of patients with monophasic NMO have permanent visual loss, and 30% have permanent paralysis in one or both legs. Among patients with relapsing NMO, 50% have blindness or paralysis within five years. In some patients (33% in one study), transverse myelitis in the cervical spinal cord resulted in respiratory failure and subsequent death. However, the spectrum of NMO has widened, due to improved diagnostic criteria; and the options for treatment have improved. As a result, researchers believe these estimates will be lowered.[18]

Epidemiology

Prevalence varies by region, ranging from 0.5 to 10 cases per 100,000 people.[1] Unlike MS, prevalence has not been found to be related to latitude.[1] NMO is more common in women than men, with women comprising over two-thirds of patients and more than 80% of those with the relapsing form of the disease.[18]

A retrospective study found that prevalence of neuromyelitis optica spectrum disorders was 1.5% among a random sample of neurological patients, with a MS:NMOSD ratio of 42:7. Among 13 NMOSD patients, 77% had long spinal cord lesions, 38% had severe optic neuritis, and 23% had brain or brainstem lesions. Only 56% had clinically definite NMO at follow-up.[72]

NMO is more common in Asians than Caucasians. In fact, Asian optic-spinal multiple sclerosis (OSMS) (which constitutes 30% of the cases of MS in Japan ) has been suggested to be identical to NMO (differences between OSMS and classic MS in Japanese patients). In the indigenous populations of tropical and subtropical regions, MS is rare; but when it appears, it often takes the form of OSMS.[73]

The majority of NMO patients have no affected relatives, and it is generally regarded as a nonfamilial condition.[18]

Rarely, NMO may occur in the context of other autoimmune diseases (e.g. connective tissue disorders, paraneoplastic syndromes) or infectious diseases. In some cases, the etiology remains unknown (idiopathic NMO).[citation needed]

History

Sir Thomas Clifford Allbutt

First reports on an association of spinal cord with optic nerve disorders date back to the late 18th and early 19th century.[74][75] However, only an 1870 report by Sir Thomas Clifford Allbutt created sustained interest on the part of neurologists and ophthalmologists in this rare syndrome.[76] In 1894, Eugène Devic and his PhD student Fernand Gault described 16 patients who had lost vision in one or both eyes and within weeks developed severe spastic weakness of the limbs, loss of sensation, and often of bladder control. They recognized these symptoms were the result of inflammation of the optic nerve and spinal cord, respectively.[74][77][78]

In 2002, Mayo Clinic researchers identified a humoral mechanism, targeting a perivascular protein, as the culprit of NMO,[26] and in 2004 an unknown specific autoantibody was found.[79] In 2005 they identified the aquaporin 4 protein as the target of the disease, and developed the first in-house test to aid in the diagnosis of NMO by detection of an antibody, AQP4-IgG, in the blood.[19] The first quantitative ELISA (enzyme-linked immunosorbent assay) kits were soon developed,[80] However, serum AQP4-IgG titer only moderately reflects disease activity, severity, or neurological prognosis.[81] Later, some other autoantibodies were found in NMO AQP4-negative cases, such as anti-MOG IgG, but some NMO anti-AQP4-negative cases still remain idiopathic.

Research directions

Since the discovery of AQP4 involvement, some research studies have focused on targeted treatment aimed at anti-aquaporin 4 antibodies. The most established method for antibody removal is plasmapheresis. A number of drugs are being studied: aquaporumab (non-pathogenic antibody blocker of AQP4-IgG binding), sivelestat (neutrophil elastase inhibitor), and eculizumab (complement inhibitor).[82]

There is little research into the primary causes of the anti-AQP4 auto-antibodies. It has been noticed that some cases could be paraneoplastic.[16]

In addition, several NMO variants have been discovered with antibodies other than those against AQP4, turning NMO into a heterogeneous disease. Six different patterns of damage have been reported in NMO, raising the possibility of six different types of auto-antibodies. As of 2019, only three of them are known.[83]

Research into new autoantibodies

An autoantibody—glial fibrillary acidic protein (GFAP)—was found in 2016, in transverse myelitis (LETM) and atypical NMO, leading to the concept of autoimmune GFAP astrocytopathy.[37]

Other autoantibody being researched is flotillin. It has been found in seronegative NMO and some MS patients.[84]

Finally, other proteins under study are connexin 43 and anti-AQP1,[85] although, as of 2015, there are only initial reports about the involvement of these proteins.[54][56]

The group AQP4+/MOG+ is very small and it can be considered a coincidence of two completely separate diseases in the same person. Assuming these cases can be verified, five different kinds of NMO are being considered:

Antibody negative neuromyelitis optica

Some cases of NMO are not due to autoantibodies. They constitute an overlap between NMO and MS.

As of 2019 some statistical studies showed that antibody-negative NMO can be classified into three groups, and that this classification has a pathogenic meaning.[87]

Later studies have increased the number of groups up to four.[88]

Notable patients

See also

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 1.37 1.38 Jarius, Sven; Paul, Friedemann; Weinshenker, Brian G.; Levy, Michael; Kim, Ho Jin; Wildemann, Brigitte (2020-10-22). "Neuromyelitis optica". Nature Reviews. Disease Primers 6 (1): 85. doi:10.1038/s41572-020-0214-9. ISSN 2056-676X. PMID 33093467. https://pubmed.ncbi.nlm.nih.gov/33093467. 
  2. ↑ 2.0 2.1 Banerjee S, Butcher R. Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Feb. Available from: https://www.ncbi.nlm.nih.gov/books/NBK571350/
  3. ↑ "Neuromyelitis optica – Symptoms and causes" (in en). https://www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/symptoms-causes/syc-20375652. 
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 Lana-Peixoto, Marco A.; Talim, Natália (2019-06-12). "Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes". Biomedicines 7 (2): 42. doi:10.3390/biomedicines7020042. ISSN 2227-9059. PMID 31212763. 
  5. ↑ A subset of anti-AQP4-negative cases is associated with antibodies against myelin oligodendrocyte glycoprotein (anti-MOG).
  6. ↑ Gaillard, Frank. "Neuromyelitis optica spectrum disorder | Radiology Reference Article | Radiopaedia.org". https://radiopaedia.org/articles/neuromyelitis-optica-spectrum-disorder?lang=gb. 
  7. ↑ Levin MC. Neuromyelitis optica spectrum disorder. Kenilworth (NJ): Merck Manuals; 2020: https://www.merckmanuals.com/en-ca/home/brain,-spinal-cord,-and-nerve-disorders/multiple-sclerosis-ms-and-related-disorders/neuromyelitis-optica-spectrum-disorder-nmosd. Accessed 2020 Nov 23
  8. ↑ Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2019;35:246-252
  9. ↑ Mayo Clinic. Neuromyelitis optica 2020; https://www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/symptoms-causes/syc-20375652. Accessed 2020 Nov 23
  10. ↑ "NMOSD, Fatigue, and Thalamic Volume - Neuromyelitis Optica Spectrum Disorder". https://www.medpagetoday.com/resource-centers/neuromyelitis-optica-spectrum-disorder/nmosd-fatigue-and-thalamic-volume/3755. 
  11. ↑ Seok, Jin Myoung; Choi, Misong; Cho, Eun Bin; Lee, Hye Lim; Kim, Byoung Joon; Lee, Kwang Ho; Song, Pamela; Joo, Eun Yeon et al. (May 23, 2017). "Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life". PLOS ONE 12 (5): e0177230. doi:10.1371/journal.pone.0177230. PMID 28542592. Bibcode: 2017PLoSO..1277230S. 
  12. ↑ Seok, Jin Myoung; Cho, Wanzee; Son, Doo-Hwan; Shin, Jong Hwa; Cho, Eun Bin; Kim, Sung Tae; Kim, Byoung Joon; Seong, Joon-Kyung et al. (January 28, 2022). "Association of subcortical structural shapes with fatigue in neuromyelitis optica spectrum disorder". Scientific Reports 12 (1): 1579. doi:10.1038/s41598-022-05531-1. PMID 35091634. Bibcode: 2022NatSR..12.1579S. https://www.nature.com/articles/s41598-022-05531-1. 
  13. ↑ Adouania, Mahdi; Mohamed, Dina Ben; Chaibi, Azza; Zouari, Rania; Rachdi, Amine; Said, Zakaria; Nabli, Fatma; Sassi, Samia Ben (December 1, 2023). "Factors Associated with Fatigue in Neuromyelitis Optica Spectrum Disorder in a Tunisian Cohort". Multiple Sclerosis and Related Disorders 80: 105245. doi:10.1016/j.msard.2023.105245. https://www.sciencedirect.com/science/article/pii/S2211034823007460. 
  14. ↑ Nasralla, Salam; Abboud, Hesham (November 2020). "Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events". Multiple Sclerosis and Related Disorders 46: 102451. doi:10.1016/j.msard.2020.102451. PMID 32835902. 
  15. ↑ 15.0 15.1 "Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later". Annals of the New York Academy of Sciences 1366 (1): 20–39. February 2016. doi:10.1111/nyas.12794. PMID 26096370. Bibcode: 2016NYASA1366...20P. 
  16. ↑ 16.0 16.1 "Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4". Multiple Sclerosis 21 (6): 791–4. May 2015. doi:10.1177/1352458515572241. PMID 25716881. 
  17. ↑ "Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study". Multiple Sclerosis 22 (9): 1192–201. August 2016. doi:10.1177/1352458515613165. PMID 26514978. 
  18. ↑ 18.0 18.1 18.2 18.3 18.4 18.5 18.6 "Neuromyelitis optica". International MS Journal 13 (2): 42–50. May 2006. PMID 16635421. 
  19. ↑ 19.0 19.1 "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel". The Journal of Experimental Medicine 202 (4): 473–7. August 2005. doi:10.1084/jem.20050304. PMID 16087714. 
  20. ↑ "The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica". Brain Pathology 24 (1): 83–97. January 2014. doi:10.1111/bpa.12099. PMID 24345222. 
  21. ↑ "Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression". Archives of Neurology 63 (7): 964–8. July 2006. doi:10.1001/archneur.63.7.964. PMID 16831965. 
  22. ↑ "Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption". Multiple Sclerosis 23 (8): 1072–1084. July 2017. doi:10.1177/1352458516672015. PMID 27682231. 
  23. ↑ "Selective localization of IgG from cerebrospinal fluid to brain parenchyma". Journal of Neuroinflammation 15 (1): 110. April 2018. doi:10.1186/s12974-018-1159-8. PMID 29665816. 
  24. ↑ "The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations". Journal of Neuroinflammation 12: 19. January 2015. doi:10.1186/s12974-015-0240-9. PMID 25626447. 
  25. ↑ "Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis". European Journal of Neurology 24 (7): 966–973. July 2017. doi:10.1111/ene.13321. PMID 28643955. 
  26. ↑ 26.0 26.1 "A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica". Brain 125 (Pt 7): 1450–61. July 2002. doi:10.1093/brain/awf151. PMID 12076996. 
  27. ↑ "Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody". Multiple Sclerosis 21 (5): 656–9. April 2015. doi:10.1177/1352458514551455. PMID 25257613. 
  28. ↑ "Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort". Multiple Sclerosis 21 (12): 1513–20. October 2015. doi:10.1177/1352458514566666. PMID 25662345. 
  29. ↑ 29.0 29.1 "Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype". Journal of Neuroinflammation 12: 46. March 2015. doi:10.1186/s12974-015-0256-1. PMID 25889963. 
  30. ↑ 30.0 30.1 "Relationship between NMO-antibody and anti-MOG antibody in optic neuritis". Journal of Neuro-Ophthalmology 32 (2): 107–10. June 2012. doi:10.1097/WNO.0b013e31823c9b6c. PMID 22157536. 
  31. ↑ "Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study". JAMA Neurology 71 (3): 276–83. March 2014. doi:10.1001/jamaneurol.2013.5857. PMID 24425068. 
  32. ↑ "Revised diagnostic criteria for neuromyelitis optica". Neurology 66 (10): 1485–9. May 2006. doi:10.1212/01.wnl.0000216139.44259.74. PMID 16717206. 
  33. ↑ 33.0 33.1 33.2 "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology 85 (2): 177–89. July 2015. doi:10.1212/WNL.0000000000001729. PMID 26092914. 
  34. ↑ 34.0 34.1 Wingerchuk, Dean M.; Banwell, Brenda; Bennett, Jeffrey L.; Cabre, Philippe; Carroll, William; Chitnis, Tanuja; de Seze, Jérôme; Fujihara, Kazuo et al. (2015-07-14). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology 85 (2): 177–189. doi:10.1212/WNL.0000000000001729. ISSN 0028-3878. PMID 26092914. 
  35. ↑ "13 Demyelinating Diseases of the CNS (Brain and Spine)". Diseases of the Brain, Head and Neck, Spine 2020–2023: Diagnostic Imaging. IDKD Springer Series. Cham, Switzerland: Springer. February 2020. pp. 165–176. doi:10.1007/978-3-030-38490-6_13. ISBN 978-3-030-38489-0. http://www.ncbi.nlm.nih.gov/books/NBK554329/. 
  36. ↑ M.C. Kruer, T.K. Koch, D.N. Bourdette, D. Chabas, E. Waubant, S. Mueller, M.A. Moscarello, J. Dalmau, R.L. Woltjer, G. Adamus, NMDA Receptor Encephalitis Mimicking Seronegative Neuromyelitis Optica, Neurology, May 04, 2010; 74 (18) Clinical/Scientific Notes, DOI: https://doi.org/10.1212/WNL.0b013e3181dc1a7f
  37. ↑ 37.0 37.1 Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis, Elia Sechi, P. Pearse Morris, Andrew McKeon, Sean Pittock, Shannon Hinson, Brian Weinshenker, Allen J. Aksamit, Evan A. Jolliffe, Anastasia Zekeridou, Dean Wingerchuk, Eoin P. Flanagan, Neurology Apr 2018, 90 (15 Supplement) S13.006
  38. ↑ Kun Jia et al., Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders, Journal of Neurological Sciences, January 16, 2019, DOI: https://doi.org/10.1016/j.jns.2019.01.024
  39. ↑ 39.0 39.1 "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology 2 (3): 295–301. March 2015. doi:10.1002/acn3.164. PMID 25815356. 
  40. ↑ "Brain magnetic resonance imaging abnormalities in neuromyelitis optica". Acta Neurologica Scandinavica 118 (4): 218–25. October 2008. doi:10.1111/j.1600-0404.2008.01012.x. PMID 18384459. 
  41. ↑ 41.0 41.1 41.2 Wingerchuk, Dean (2006). "Neuromyelitis Optica (Devic's Syndrome)". http://www.myelitis.org/rnds2006/Wingerchuk_NMO_Rare%20Neuroimm_062406_final.pdf. Retrieved 2007-01-05. 
  42. ↑ "Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges". Neurology 80 (24): 2176–7. June 2013. doi:10.1212/WNL.0b013e318296ea22. PMID 23658387. 
  43. ↑ "Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity". Neurology 80 (24): 2194–200. June 2013. doi:10.1212/WNL.0b013e318296e917. PMID 23658379. 
  44. ↑ "Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations". Multiple Sclerosis 10 (1): 2–4. February 2004. doi:10.1191/1352458504ms988oa. PMID 14760945. 
  45. ↑ "Long spinal cord lesions in a patient with pathologically proven multiple sclerosis". Journal of Clinical Neuroscience 42: 106–108. August 2017. doi:10.1016/j.jocn.2017.03.022. PMID 28465080. 
  46. ↑ "Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder". Multiple Sclerosis Journal – Experimental, Translational and Clinical 3 (4): 2055217317742425. 2017. doi:10.1177/2055217317742425. PMID 29204291. 
  47. ↑ "Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease". Acta Neuropathologica Communications 5 (1): 95. December 2017. doi:10.1186/s40478-017-0495-8. PMID 29208041. 
  48. ↑ "Neuromyelitis optica". Spinal Cord 43 (11): 631–4. November 2005. doi:10.1038/sj.sc.3101758. PMID 15968305. 
  49. ↑ "Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy". Trends in Molecular Medicine 7 (3): 115–21. March 2001. doi:10.1016/s1471-4914(00)01909-2. PMID 11286782. 
  50. ↑ "Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis". Frontiers in Neurology 4: 125. 2013. doi:10.3389/fneur.2013.00125. PMID 24032025. 
  51. ↑ "[Clinical concept, etiology and pathology of neuromyelitis optica]". Nihon Rinsho. Japanese Journal of Clinical Medicine 72 (11): 1897–902. November 2014. PMID 25518368. 
  52. ↑ "Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab". BMC Neurology 14: 247. December 2014. doi:10.1186/s12883-014-0247-3. PMID 25516429. 
  53. ↑ Alexander B. Ramos et al., A case of NMO spectrum disorder presenting with undiagnosed Sjogren's syndrome and a single, atypical tumefactive lesion: A clinical conundrum, Neur. Sciences, December 15, 2017Volume 383, Pages 216–218, DOI: https://doi.org/10.1016/j.jns.2017.10.036
  54. ↑ 54.0 54.1 "Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica". PLOS ONE 8 (8): e72919. 2013. doi:10.1371/journal.pone.0072919. PMID 23991165. Bibcode: 2013PLoSO...872919M. 
  55. ↑ "AQP4 antibody serostatus: Is its luster being lost in the management and pathogenesis of NMO?". Neurology 81 (14): 1186–8. October 2013. doi:10.1212/WNL.0b013e3182a6cc23. PMID 23997154. 
  56. ↑ 56.0 56.1 "Early disruption of glial communication via connexin gap junction in multiple sclerosis, Baló's disease and neuromyelitis optica". Neuropathology 35 (5): 469–80. October 2015. doi:10.1111/neup.12211. PMID 26016402. 
  57. ↑ 57.0 57.1 "Neuromyelitis optica - Diagnosis and treatment - Mayo Clinic". https://www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/diagnosis-treatment/drc-20375655. 
  58. ↑ 58.0 58.1 58.2 Kowarik, Markus C.; Soltys, John; Bennett, Jeffrey L. (March 2014). "The Treatment of Neuromyelitis Optica". Journal of Neuro-Ophthalmology 34 (1): 70–82. doi:10.1097/WNO.0000000000000102. ISSN 1070-8022. PMID 24531318. 
  59. ↑ 59.0 59.1 Wallach, AI; Tremblay, M; Kister, I (February 2021). "Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.". Neurologic Clinics 39 (1): 35–49. doi:10.1016/j.ncl.2020.09.003. PMID 33223088. 
  60. ↑ Kimbrough, Dorlan J.; Fujihara, Kazuo; Jacob, Anu; Lana-Peixoto, Marco A.; Isabel Leite, Maria; Levy, Michael; Marignier, Romain; Nakashima, Ichiro et al. (October 2012). "Treatment of neuromyelitis optica: Review and recommendations". Multiple Sclerosis and Related Disorders 1 (4): 180–187. doi:10.1016/j.msard.2012.06.002. PMID 24555176. 
  61. ↑ "FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system". U.S. Food and Drug Administration (FDA) (Press release). 27 June 2019. Retrieved 28 June 2019.
  62. ↑ "FDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal Cord". U.S. Food and Drug Administration (FDA) (Press release). 2020-06-11. Retrieved 2020-06-21.
  63. ↑ "Enspryng (satralizumab)". https://www.roche.com/products/product-details.htm?productId=6f4b47a2-7ca9-4768-bf1a-6d813702f5b6. 
  64. ↑ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". 17 August 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord. 
  65. ↑ "Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)". Archives of Neurology 63 (7): 957–63. July 2006. doi:10.1001/archneur.63.7.957. PMID 16831964. 
  66. ↑ "Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis". Multiple Sclerosis 13 (8): 968–74. September 2007. doi:10.1177/1352458507077189. PMID 17623727. 
  67. ↑ "Neuromyelitis optica". Current Opinion in Neurology 20 (3): 255–60. June 2007. doi:10.1097/WCO.0b013e32814f1c6b. PMID 17495617. 
  68. ↑ "Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up". Journal of the Neurological Sciences 372: 92–96. January 2017. doi:10.1016/j.jns.2016.11.016. PMID 28017256. 
  69. ↑ "Autologous haematopoietic stem cell transplantation for neurological diseases". Journal of Neurology, Neurosurgery, and Psychiatry 89 (2): 147–155. February 2018. doi:10.1136/jnnp-2017-316271. PMID 28866625. 
  70. ↑ Baghbanian, Seyed Mohammad; Asgari, Nasrin; Sahraian, Mohammad Ali; Moghadasi, Abdorreza Naser (May 2018). "A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment" (in en). Journal of the Neurological Sciences 388: 222–231. doi:10.1016/j.jns.2018.02.028. PMID 29478727. https://findresearcher.sdu.dk/ws/files/141817075/A_comparison_of_pediatric_and_adult_neuromyelitis_optica_spectrum_disorders_A_review_of_clinical_manifestation_diagnosis_and_treatment.pdf. 
  71. ↑ "Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients". Multiple Sclerosis 17 (12): 1527–30. December 2011. doi:10.1177/1352458511412995. PMID 21828202. 
  72. ↑ "Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution". Journal of Neurology 256 (11): 1891–8. November 2009. doi:10.1007/s00415-009-5171-x. PMID 19479168. 
  73. ↑ "Role of return migration in the emergence of multiple sclerosis in the French West Indies". Brain 128 (Pt 12): 2899–910. December 2005. doi:10.1093/brain/awh624. PMID 16183661. 
  74. ↑ 74.0 74.1 "The history of neuromyelitis optica". Journal of Neuroinflammation 10 (1): 8. January 2013. doi:10.1186/1742-2094-10-8. PMID 23320783. 
  75. ↑ "The history of neuromyelitis optica. Part 2: 'Spinal amaurosis', or how it all began". Journal of Neuroinflammation 16 (1): 280. November 2018. doi:10.1186/s12974-019-1594-1. PMID 31883522. 
  76. ↑ "On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica". Journal of Neurology 260 (1): 100–4. January 2013. doi:10.1007/s00415-012-6594-3. PMID 22782261. 
  77. ↑ "Myélite subaiguë compliquée de névrite optique" (in fr). Bull Med 8: 1033. 1894. 
  78. ↑ T. Jock Murray (2005). Multiple Sclerosis: The History of a Disease. New York: Demos Medical Publishing. ISBN 978-1-888799-80-4. 
  79. ↑ "A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis". Lancet 364 (9451): 2106–12. 2004. doi:10.1016/S0140-6736(04)17551-X. PMID 15589308. 
  80. ↑ Isobe, Noriko; Yonekawa, Tomomi; Matsushita, Takuya; Kawano, Yuji; Masaki, Katsuhisa; Yoshimura, Satoshi; Fichna, Jakub; Chen, Shu et al. (2012). "Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica". Multiple Sclerosis Journal 18 (11): 1541–1551. doi:10.1177/1352458512443917. PMID 22526930. 
  81. ↑ "Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica". Neurochemical Research 38 (5): 997–1001. May 2013. doi:10.1007/s11064-013-1009-0. PMID 23456674. 
  82. ↑ "Aquaporin 4 and neuromyelitis optica". The Lancet. Neurology 11 (6): 535–44. June 2012. doi:10.1016/S1474-4422(12)70133-3. PMID 22608667. 
  83. ↑ "Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica". Acta Neuropathologica 125 (6): 815–27. June 2013. doi:10.1007/s00401-013-1116-7. PMID 23579868. 
  84. ↑ "Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis". Journal of Neuroinflammation 14 (1): 123. June 2017. doi:10.1186/s12974-017-0900-z. PMID 28645295. 
  85. ↑ 85.0 85.1 Tzartos JS; Stergiou C; Kilidireas, K; Zisimopoulou, P; Thomaidis, T; Tzartos, SJ (2013). "Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders". PLOS ONE 8 (9): e74773. doi:10.1371/journal.pone.0074773. PMID 24086369. Bibcode: 2013PLoSO...874773T. 
  86. ↑ Stork, Lidia; Ellenberger, David; Ruprecht, Klemens; Reindl, Markus; Beißbarth, Tim; Friede, Tim; Kümpfel, Tania; Gerdes, Lisa A. et al. (2020). "Antibody signatures in patients with histopathologically defined multiple sclerosis patterns". Acta Neuropathologica 139 (3): 547–564. doi:10.1007/s00401-019-02120-x. PMID 31950335. 
  87. ↑ Tianrong Yeo; Fay Probert; Maciej Jurynczyk; Megan Sealey; Ana Cavey et al. (October 28, 2019). "Classifying the antibody-negative NMO syndromes, Clinical, imaging, and metabolomic modeling". Neurology 6 (6): e626. doi:10.1212/NXI.0000000000000626. PMID 31659123. 
  88. ↑ Yeo, Tianrong; Probert, Fay; Jurynczyk, Maciej; Sealey, Megan; Cavey, Ana; Claridge, Timothy D. W.; Woodhall, Mark; Waters, Patrick et al. (1 November 2019). "Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling". Neurology: Neuroimmunology & Neuroinflammation 6 (6): e626. doi:10.1212/NXI.0000000000000626. PMID 31659123. 
Classification
External resources



Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Neuromyelitis_optica_spectrum_disorder&oldid=3273793"